Ausgabe 4/2019
Inhalt (25 Artikel)
Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer
G. Roviello, F. U. Conter, E. Mini, D. Generali, M. Traversini, D. Lavacchi, S. Nobili, N. Sobhani
Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer
Annie Roys, Xing Chang, Yang Liu, Xiaobo Xu, Yingliang Wu, Daiying Zuo
Current status of nanomedicine in the chemotherapy of breast cancer
A. I. Fraguas-Sánchez, C. Martín-Sabroso, A. Fernández-Carballido, A. I. Torres-Suárez
Population pharmacokinetics of trabectedin in adolescent patients with cancer
Italo Poggesi, Belén Valenzuela, Daniele Ouellet, Martha Gonzalez, Vera Hillewaert, Sylvain Baruchel, Elizabeth Fox, Juan Jose Perez-Ruixo
Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway
Zhe Cha, Jianzhang Cheng, Hui Xiang, Jingjing Qin, Yujia He, Zhiping Peng, Jianhua Jia, Huarong Yu
Species-specific optimization of PEG~SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft
Shaun D. Fontaine, Byron Hann, Ralph Reid, Gary W. Ashley, Daniel. V. Santi
A simple ex vivo bioassay for 5-FU transport into healthy buccal mucosal cells
Kathryn E. Burns, Daniel Allright, David Porter, Michael P. Findlay, Nuala A. Helsby
Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects
Vassilios Aslanis, Kenichi Umehara, Felix Huth, Taoufik Ouatas, Savita Bharathy, Andrew Avigdor Butler, Wen Zhou, Brian Gadbaw
A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer
Cody J. Peer, Keith T. Schmidt, Jessica D. Kindrick, Joel R. Eisner, Victoria V. Brown, Edwina Baskin-Bey, Ravi Madan, William D. Figg
Identification of pharmacodynamic biomarkers and common molecular mechanisms of response to genotoxic agents in cancer cell lines
Dong-Joon Min, Yingdong Zhao, Anne Monks, Alida Palmisano, Curtis Hose, Beverly A. Teicher, James H. Doroshow, Richard M. Simon
Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study
Javier Munárriz, Gaspar Reynés, Luisa Sánchez-Lorenzo, Emilio Esteban, Laura Basterretxea, Leticia de Avila-Lizárraga, Miguel Angel Climent, María José Juan-Fita, Corina Escoín, Javier Puente, Javier Cassinello, Sergio Vázquez, Isabel Chirivella
A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24
Mansoor Raza Mirza, Troels K. Bergmann, Morten Mau-Sørensen, René dePont Christensen, Elisabeth Åvall-Lundqvist, Michael J. Birrer, Morten Jørgensen, Henrik Roed, Susanne Malander, Flemming Nielsen, Ulrik Lassen, Kim Brøsen, Line Bjørge, Johanna Mäenpää
A drug–drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics
Jianke Li, Denise Trone, Jeanne Mendell, Patrick O’Donnell, Natalie Cook
Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma
Mi Na Kim, Seung Min Lee, Jin Sung Kim, Seong Gyu Hwang
A two centers study of postoperative adjuvant chemotherapy with S-1 versus SOX/XELOX regimens for gastric cancer after D2 resection: a cohort study
Song Zheng, Yao Zhou, Yangcheng Sun, Zhen Wang, Yidan Lu
Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors
Samuel J. Reddick, Olivia Campagne, Jie Huang, Arzu Onar-Thomas, Alberto Broniscer, Amar Gajjar, Clinton F. Stewart
Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial
F. J. Esteva, Y. V. Baranau, V. Baryash, A. Manikhas, V. Moiseyenko, G. Dzagnidze, E. Zhavrid, D. Boliukh, D. Stroyakovskiy, J. Pikiel, A. E. Eniu, R. K. Li, A. V. Rusyn, B. Tiangco, S. J. Lee, S. Young Lee, S. Y. Yu, J. Stebbing
Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma
Eisei Kondo, Takashi Ikeda, Hiroaki Goto, Momoko Nishikori, Naoko Maeda, Kimikazu Matsumoto, Hideo Kitagawa, Naoto Noda, Saori Sugimoto, Junichi Hara
FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer
Mingyou Xing, Jun Wang, Qin Yang, Yu Wang, Jiansha Li, Jing Xiong, Sheng Zhou
Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer
Atsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, Ayako Shiono, Yu Miura, Kosuke Hashimoto, Fuyumi Nishihara, Yoshitake Murayama, Kunihiko Kobayashi, Hiroshi Kagamu
Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study
Sacha I. Rothschild, Daniel Betticher, Reinhard Zenhäusern, Sandro Anchisi, Roger von Moos, Miklos Pless, Peter Moosmann, Razvan A. Popescu, Antonello Calderoni, Marco Dressler, Daniel Rauch, Stefanie Pederiva, Regina Woelky, Claudia Papet, Vera Bühler, Markus Borner
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Ken Ogasawara, Simon Zhou, Gopal Krishna, Maria Palmisano, Yan Li
A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors
Janice M. Mehnert, Amanda D. Kaveney, Jyoti Malhotra, Kristen Spencer, Daniella Portal, Susan Goodin, Antoinette R. Tan, Joseph Aisner, Rebecca A. Moss, Hongxia Lin, Joseph R. Bertino, Darlene Gibbon, Laurence A. Doyle, Eileen P. White, Mark N. Stein
A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)
Jeffrey Melson Clarke, Gerard C. Blobe, John H. Strickler, Hope Elizabeth Uronis, S. Yousuf Zafar, Michael Morse, Evan Dropkin, Leigh Howard, Margot O’Neill, Christel N. Rushing, Donna Niedzwiecki, Hollie Watson, Emily Bolch, Christy Arrowood, Yingmiao Liu, Andrew B. Nixon, Herbert I. Hurwitz
A pilot study of first-line olaratumab, doxorubicin and ifosfamide in patients with metastatic soft tissue sarcoma
Olga Vornicova, Nissim Haim, Gil Bar-Sela